HER2-positive breast cancer

Exam relevance: in 38 of more than 150 board exam reports · rank 15

Specialty
Gynaecology · Breast
Images
Ultrasound 1 · Histology & cytology 1
Exam relevance
38 of more than 150 reports · rank 15
In the app
1 flashcard · GynFuchs
Last updated
10/2026 · Dr. Pascal Bafteh
Contents
  1. Images (2)
  2. Definition
  3. Classification
  4. Occurrence & epidemiology
  5. Aetiopathogenesis
  6. Clinical features
  7. Diagnosis
  8. Treatment principles
  9. Keep learning in the app
  10. Further reading (selection)
  11. Cross-references

Images (2)

HER2-positive breast cancer – Breast ultrasound: hypoechoic, ill-defined lesion with posterior acoustic shadowingUltrasound
Breast ultrasound: hypoechoic, ill-defined lesion with posterior acoustic shadowingImage: SCiardullo, “Caso 1 Ecografia 1” (Wikimedia Commons) · CC BY-SA 3.0 · Source · cropped
HER2-positive breast cancer – Breast ultrasound: large, heterogeneous solid lesion — histologically a phyllodes tumourHistology & cytology
Breast ultrasound: large, heterogeneous solid lesion — histologically a phyllodes tumourImage: Cerevisae (Wikimedia Commons) · CC BY-SA 4.0 · Source · cropped
1 / 2

Definition

  • Breast cancer with amplification of the HER2 gene and/or overexpression of the HER2 protein, a transmembrane tyrosine kinase receptor of the HER family of growth factor receptors (HER1–4).

Classification

Molecular subtypes

  • Luminal A: A Luminal A carcinoma is hormone receptor-positive, HER2-negative, well-differentiated with a low Ki-67.
  • Luminal B: A Luminal B carcinoma is hormone receptor-positive with a high Ki-67 or poorer grade, HER2 negative or positive.
  • Triple-negative: In triple-negative breast cancer: oestrogen receptor, progesterone receptor, and HER2 are all negative.
  • HER2-positive tumours may be hormone receptor-positive (luminal B subtype) or hormone receptor-negative; the latter form the HER2-positive (HER2-enriched) subtype.
  • HER2-low denotes tumours with an immunohistochemical score of 1+ or 2+ without amplification on in situ hybridisation; they contain some HER2 protein but not enough to be classified as HER2-positive.
  • HER2-low is a heterogeneous group, and whether it constitutes a distinct entity remains controversial.

Occurrence & epidemiology

Epidemiology

  • About 15–20% of breast cancers are HER2-positive, about 40–60% are HER2-low, and 20–45% show no HER2 expression (score 0).

Aetiopathogenesis

Aetiology and pathogenesis

  • The HER2 gene lies on chromosome 17 (band q21); tumour tissue may have up to 25–50 gene copies, up to a 40- to 100-fold increase in protein and up to 2 million receptors on the cell surface.
  • HER2 itself binds no ligand but is activated by homo- or heterodimerisation with the ligand-bound receptors HER1, HER3 and HER4, mainly switching on the MAPK and PI3K signalling pathways.
  • These pathways promote cell proliferation, invasion and angiogenesis and protect cells against apoptosis.

Clinical features

More facts from the study questions

  • The Elston and Ellis grading system is an established system for assessing the aggressiveness of breast carcinoma.
  • It is based on the histological evaluation of three criteria: tubule formation, nuclear pleomorphism and mitotic rate.
  • The definition of triple-negative breast carcinoma is the lack of expression of all three relevant receptors.
  • It is oestrogen receptor-negative, progesterone receptor-negative and HER2-negative.
  • HER2 status is primarily determined by immunohistochemistry (IHC).
  • Invasive lobular carcinoma is characterised by diffuse growth and is difficult to delineate.
  • HER2 positivity gives the tumour a more aggressive behaviour, with higher recurrence rates and shorter disease-free and overall survival.
  • HER2-positive carcinomas tend to grow quickly, faster than tumours with less HER2 (HER2-negative or HER2-low).

Diagnosis

  • HER2 status is determined on tumour tissue; only immunohistochemistry for protein expression and in situ hybridisation for gene status are clinically validated.
  • A tumour is HER2-positive with an immunohistochemical score of 3+ or a score of 2+ with amplification demonstrated by in situ hybridisation; 2+ without amplification, 1+ and 0 count as HER2-negative.
  • Pre-analytical and analytical factors such as tissue fixation, processing, staining technique and scoring criteria largely determine the reliability of the result.

Treatment principles

  • The basis is HER2-targeted antibody therapy combined with chemotherapy, often given neoadjuvantly before surgery; the response determines further treatment after surgery.
  • Surgery and radiotherapy follow general principles, supplemented by endocrine therapy if hormone receptors are positive.
  • Because of possible cardiotoxicity, cardiac function is monitored regularly; all steps are decided by the tumour board of a breast centre.

Specific treatment regimens with drugs and doses are covered in the GynFuchs app.

Keep learning in the app

In the GynFuchs app you can learn HER2-positive breast cancer with flashcards, exam questions and image tasks (colposcopy, ultrasound, CTG) – free, in your browser or as an app.

In the app: 1 flashcard on this topic

Open in browser  About GynFuchs →

Further reading (selection)

  1. HER2 expression in breast cancer: evidence gaps and challenges
  2. HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review
  3. National Cancer Institute: Breast Cancer Biomarkers
  4. DocCheck Flexikon, Mammakarzinom

Cross-references

Keep learning

Keep learning with flashcards, exam questions and spot diagnoses in the GynFuchs app – free, in your browser or as an app.

Related pages: Hereditary breast and ovarian cancer syndrome (BRCA) · Hormone receptor-positive breast cancer (luminal A and B) · Inflammatory breast cancer

Note: Learning content from the GynFuchs app (flashcards, exam questions, image cases) for medical education – not a treatment recommendation and no substitute for diagnosis or treatment decisions in individual cases. Treatment and management are deliberately not covered on this page.